氯雷他定联合白芍总苷治疗慢性湿疹的效果观察

Effects of loratadine combined with total glucosides of paeony on patients with chronic eczema

目的:研究氯雷他定与白芍总苷联合治疗慢性湿疹的临床疗效。方法:抽取2016年5月至2019年5月于开封市人民医院治疗的慢性湿疹患者100例进行研究,按照单双号分为观察组(单数组)与对照组(双数组),每组50例;两组患者给予常规治疗,对照组给予氯雷他定治疗,观察组给予氯雷他定联合白芍总苷治疗,两组患者均进行3周的治疗,并于治疗结束3个月后复诊1次。比较两组患者治疗有效率、免疫功能指标、细胞因子水平、不良反应发生率及复发率情况。结果:观察组治疗有效率高于对照组(P<0.05);治疗后,两组患儿皮损面积、皮损评分、皮肤瘙痒评分及EASI评分均降低(P均<0.05),且观察组治疗后与对照组比较,差异有统计学意义(P<0.05);治疗后,两组患者CD4+、CD4+/CD8+、Th1/Th2水平均升高(P均<0.05),CD8+降低(P<0.05),且观察组治疗后与对照组比较差异有统计学意义(P<0.05);治疗后,两组患者白细胞介素-4(IL-4)、神经生长因子(IL-10)、白细胞介素-10(NGF)水平均降低(P均<0.05),干扰素-γ(INF-γ)、转化生长因子-β(TGF-β)均显著升高(P均<0.05),且观察组治疗后与对照组比较,差异有统计学意义(P<0.05);治疗期间,两组患者不良反应发生率比较,差异未见统计学意义(P>0.05);观察组治疗后3个月内复发2例(4.00%),对照组复发5例(10.00%),两组患者的慢性湿疹复发率比较差异有统计学意义(P<0.05)。结论:氯雷他定联合白芍总苷治疗慢性湿疹临床疗效显著,能显著改善患者免疫功能、细胞因子,有效降低炎性反应及慢性湿疹复发率,安全性高。

Objective To study the clinical efficacy of loratadine combined with total glucosides of paeony in the treatment of chronic eczema.Methods A total of 100 patients with chronic eczema treated in Kaifeng People’s Hospital from May 2016 to May 2019 were selected for the study,and they were divided into observation group(single array)and control group(double array)according to single and double number,with 50 cases in each group.Two groups of patients were given routine treatment,the control group was given loratadine,and observation group was given loratadine combined with total glucosides of paeony,and the two groups were treated for 3 weeks,and given a subsequent visit at 3 months after the end of treatment.The treatment efficiency,immune function indexes,cytokines levels,incidence of adverse reactions and recurrence rate were compared between the two groups.Results The treatment efficiency in observation group was significantly higher than that in control group(P<0.05).After treatment,the skin lesion area,skin lesion score,skin itching score and EASI score were significantly decreased in the two groups(all P<0.05),and the indexes in observation group after treatment were significantly different from those in control group(P<0.05).After treatment,the levels of CD4+,CD4+/CD8+and Th1/Th2 in the two groups were significantly increased(all P<0.05)while the level of CD8+was significantly decreased(P<0.05),and the indexes in observation group after treatment were significantly different from those in control group(P<0.05).After treatment,the levels of interleukin-4(IL-4),interleukin-10(IL-10)and nerve growth factor(NGF)in the two groups were significantly decreased(P<0.05),while the levels of interferon-γ(INF-γ)and transforming growth factor(TGF-β)were significantly increased(P<0.05),and the indexes in observation group after treatment were significantly different from those in control group(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Within 3 months after treatment,there were 2 cases(4.00%)of recurrence in observation group and 5 cases(10.00%)of recurrence in control group,and there was no significant difference in the recurrence rate of chronic eczema between the two groups(P<0.05).Conclusions Loratadine combined with total glucosides of paeony has significantclinical efficacyin the treatment of chronic eczema,and it can significantly improve the immune function and cytokines of patients,effectively reduce the inflammatory response and the recurrence rate of chronic eczema,with high safety.